MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has received a U.S. patent covering the use of its drug candidate buntanetap to prevent and treat neurological injuries linked to brain infections.
U.S. Patent No. 12,582,632 B2 includes claims for the use of buntanetap and related compounds to address neurological damage associated with viral, bacterial, fungal, and other infections, according to the company.
The patent also covers preventive use in individuals at risk of exposure and treatment for those already affected, with protection extending through 2044.
Annovis said the patent reflects research suggesting that infections may contribute to Alzheimer’s disease by triggering overproduction of proteins such as amyloid-beta and tau, which can accumulate and lead to neurodegeneration over time.
Buntanetap is designed to reduce the production of these proteins at the translational level, targeting processes linked to disease development.
“This patent is an important addition to our growing intellectual property estate,” said Maria Maccecchini, president and chief executive officer of Annovis. “There is a clear need to identify methods of treating and preventing neurodegeneration resulting from the overexpression of proteins that occur during microbial and viral infections.”
Annovis is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases, including Alzheimer’s and Parkinson’s.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.